By a News Reporter-Staff News Editor at Women's Health Weekly -- Researchers detail new data in Oncology. According to news reporting from Cambridge, Massachusetts, by NewsRx journalists, research stated, "A single nanoparticle platform has been developed through the modular and controlled layer-by-layer process to codeliver siRNA that knocks down a drug-resistance pathway in tumor cells and a chemotherapy drug to challenge a highly aggressive form of triple-negative breast cancer. Layer-by-layer films were formed on nanoparticles by alternately depositing siRNA and poly-L-arginine; a single bilayer on the nanoparticle surface could effectively load up to 3500 siRNA molecules, and the resulting LbL nanoparticles exhibit an extended serum half-life of 28 h. In animal models, one dose via intravenous administration significantly reduced the target gene expression in the tumors by almost 80%."
The news correspondents obtained a quote from the research from the Massachusetts Institute of Technology, "By generating the siRNA-loaded film atop a doxorubicin-loaded liposome, we identified an effective combination therapy with siRNA targeting multidrug resistance protein 1, which significantly enhanced doxorubicin efficacy by 4 fold in vitro and led to up to an 8-fold decrease in tumor volume compared to the control treatments with no observed toxicity. The results indicate that the use of layer-by-layer films to modify a simple liposomal doxorubicin delivery construct with a synergistic siRNA can lead to significant tumor reduction in the cancers that are otherwise nonresponsive to treatment with Doxil or other common chemotherapy drugs."
According to the news reporters, the research concluded: "This approach provides a potential strategy to treat aggressive and resistant cancers, and a modular platform for a broad range of controlled multidrug therapies customizable to the cancer type in a singular nanoparticle delivery system."
For more information on this research see: Layer-by-Layer Nanoparticles for Systemic Codelivery of an Anticancer Drug and siRNA for Potential Triple-Negative Breast Cancer Treatment. ACS Nano, 2013;7(11):9571-9584. ACS Nano can be contacted at: Amer Chemical Soc, 1155 16TH St, NW, Washington, DC 20036, USA. (American Chemical Society - www.acs.org; ACS Nano - www.pubs.acs.org/journal/ancac3)
Our news journalists report that additional information may be obtained by contacting Z.J. Deng, MIT, Dept. of Chem Engn, Cambridge, MA 02139, United States. Additional authors for this research include S.W. Morton, E. Ben-Akiva, E.C. Dreaden, K.E. Shopsowitz and P.T. Hammond (see also Oncology).
Keywords for this news article include: Antibiotics - Antineoplastics, Pharmaceuticals, Drugs, siRNA, Genetics, Oncology, Cambridge, Treatment, Chemotherapy, Nanoparticle, Massachusetts, United States, Breast Cancer, Nanotechnology, Women's Health, Combination Therapy, Emerging Technologies, Small Interference RNAs, North and Central America
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC